
[http://dx.doi.org/10.1177/2168479016632271](http://dx.doi.org/10.1177/2168479016632271)

[http://dx.doi.org/10.1016/j.jhealeco.2016.01.012](http://dx.doi.org/10.1016/j.jhealeco.2016.01.012)


[http://dx.doi.org/10.1208/s12248-015-9833-6](http://dx.doi.org/10.1208/s12248-015-9833-6)


[http://dx.doi.org/10.1177/2168479015625712](http://dx.doi.org/10.1177/2168479015625712)

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kaitin KI, editor. Amendments reduce number of patients, but at high cost, longer study times. *Tufts Center for the Study of Drug Development Impact Report*. 2016 Jan/Feb;18(1)** [RS 3601]


http://dx.doi:10.1038/nrd4759


http://www.pharmoutsourcing.com/Featured-Articles/177660-The-Unintended-Inefficiencies-of-Outsourcing-Practice/

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


[http://dx.doi.org/10.1002/cpt.194](http://dx.doi.org/10.1002/cpt.194)

[http://dx.doi.org/10.1016/j.clinthera.2015.07.004](http://dx.doi.org/10.1016/j.clinthera.2015.07.004)

[http://dx.doi.org/10.1016/j.clinthera.2015.05.514](http://dx.doi.org/10.1016/j.clinthera.2015.05.514)


[http://dx.doi.org/10.1007/s40264-015-0310-z](http://dx.doi.org/10.1007/s40264-015-0310-z)

http://dx.doi.org/10.1136/bmj.h3333


http://dx.doi.org/10.1177/2168479015587362

http://dx.doi.org/10.1177/2168479015586003


http://dx.doi.org/10.1056/NEJMc1504317

Getz KA. The transformative promise of patient centric R&D. *Pharmaceutical Business Review*. Online publish date: May 7, 2015. [RS 3520] 

http://dx.doi.org/10.1177/2168479015583727

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1177/2168479015580382

http://dx.doi.org/10.1177/2168479015579521

http://dx.doi.org/10.1177/2168479015578156

http://dx.doi.org/10.1007/s40291-015-0138-3


http://dx.doi.org/10.1016/j.clinthera.2015.02.026


http://www.pharmexec.com/meeting-unmet-medical-needs-disparity-dilemma-0


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1377/hlthaff.2014.1047

http://dx.doi.org/10.1377/hlthaff.2014.1023


http://dx.doi.org/10.2217/bmm.14.84

http://dx.doi.org/10.2217/bmm.14.66


Stergiopoulos S, Surgeon L. The facilitated clinical trial protocol review: is the theory being put into good practice? *Chimica Oggi [Chemistry Today]*. 2014;32(6):52-56. [RS 3439]  

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

Kaitin KI, editor. CNS drugs take longer to develop, have lower success rates, than other drugs. Tufts Center for the Study of Drug Development Impact Report. 2014 Nov/Dec;16(6)** [RS 3438]


**Cost Study Press Event Webcast and Briefing, November 18, 2014**
To access materials related to the Cost Study click here: http://csdd.tufts.edu/news/complete_story/cost_study_press_event_webcast


**This publication is for sale at our website http://csdd.tufts.edu/reports**


http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=845307&pageID=1&sk=&date=

http://dx.doi.org/10.1016/j.clinthera.2014.05.004


Getz KA. Q&A with Jean Burns: Insights from a study volunteer. *Applied Clinical Trials Online*. Online publish date: May 28, 2014. [RS 3422] 


http://dx.doi.org/10.3390/ijerph110505069

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1002/9781118783344.ch1


Getz KA. Coming to terms with interrupted drug development programs. Applied Clinical Trials. 2014;23(4/5):22-23. [RS 3417b] 

http://dx.doi.org/10.1038/nrd4325

http://dx.doi.org/10.1038/clpt.2014.14


http://www.manhattan-institute.org/html/fda_07.htm#U1_t61dUinw


http://csdd.tufts.edu/reports/ebooks

**This publication is for sale at our website  http://csdd.tufts.edu/reports

http://dx.doi.org/10.3390/jpm4020163

http://dx.doi.org/10.1177/2168479014525957


Milne C-P, Davis J. The Pediatric studies initiative: after 15 years have we reached the limits of the law? *Clinical Therapeutics.* 2014;36(2):156-162. [RS 3407]
http://dx.doi.org/10.1016/j.clinthera.2013.11.007


http://dx.doi.org/10.4155/cli.13.134

http://dx.doi.org/10.1177/2168479014521419


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1517/21678707.2013.819289

http://dx.doi.org/10.1038/clpt.2013.117


http://dx.doi.org/10.1177/2168479013494386

Milne CP. On the partnering path from the US to Asia: how far, how fast for university-industry collaborations? *Pharma Focus Asia*. 2013;(18):40-45. [RS 3323]  
http://www.pharmafocusasia.com/strategy/partnering-path-us-asia


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1016/j.clinthera.2013.04.004


http://www.panstanford.com/books/9789814316996.html


http://images2.advanstar.com/PixelMags/pharma-executive/digitaledition/05-2013.html#38


http://dx.doi.org/10.3111/13696998.2013.793693

Getz KA. Building clinical trial awareness for patients: why not try the pharmacist? *Pharmaceutical Executive*. Published March 1, 2013 [web document] [RS 3315]

**This publication is for sale at our website** http://csdd.tufts.edu/reports


**This publication is for sale at our website http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1097/MJT.0b013e318269198f


Kaitin KI, editor. 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Jan/Feb;15(1)** [RS 3302]

http://dx.doi.org/10.1177/2168479012469947


http://dx.doi.org/10.1016/j.anai.2012.11.014

http://dx.doi.org/10.1634/theoncologist.2012-0235


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.1586/ecp.12.44


http://dx.doi.org/10.1007/s12031-012-9803-8


http://dx.doi.org/10.1097/MJT.0b013e318262316f


http://www.topra.org/regulatory-rapporteur-oct-2012


http://dx.doi.org/10.1007/BF03262374


Kaitin KI. Translational research and the evolving landscape for biomedical innovation. *Journal of Investigative Medicine*. 2012;60(7):995-998 [RS 3228]

http://dx.doi.org/10.231/JIM.0b013e318268694f

**This publication is for sale at our website  [http://csdd.tufts.edu/reports]**
http://dx.doi.org/10.1586/erp.12.25


http://dx.doi.org/10.1177/0092861512453040


http://dx.doi.org/10.1038/clpt.2012.87


http://www.pharmafocusasia.com/research_development/application-Biopharmaceutics-Classification-System-Drug-Development.htm


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1016/j.drudis.2012.04.006

http://dx.doi.org/10.4161/mabs.19931


http://dx.doi.org/10.1586/ecp.12.7

http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=763940&sk=&date=&&pageID=1

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1136/medethics-2011-100411

http://dx.doi.org/10.1016/j.nbt.2012.02.001

http://dx.doi.org/10.4161/mabs.4.2.18812


Getz KA. Profound changes in the outsourcing landscape. Pharmaceutical Executive. Published February 29, 2012. [web document] [RS 3206]

http://dx.doi.org/10.1038/nrd3677

http://dx.doi.org/10.1038/clpt.2011.338


**This publication is for sale at our website  http://csdd.tufts.edu/reports


Kaitin KI. Creating innovation nodes to meet unmet medical needs. *Pharmaceutical Technology*. 2011;35(12):27 [RS 3132]

Getz KA. Transforming legacy R&D through open innovation. *ACRP Monitor*. 2011;25(7):17-21 [RS 3131b]

http://dx.doi.org/10.1089/pop.2011.0020


http://dx.doi.org/10.1038/tpj.2011.63

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. *Value in Health.* 2011;14:944-952 [RS 3127]
http://dx.doi.org/10.1016/j.jval.2011.05.004

http://dx.doi.org/10.4161/mabs.3.5.17334

http://www.biopharminternational.com/biopharm/Final+Word/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/750858

Milne C-P. The case for pediatric exclusivity. *Pharmaceutical Technology.* 2011;35(9):38 [RS 3126]
http://pharmtech.findpharma.com/pharmtech/Drug+Delivery/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/738366

http://dx.doi.org/10.1586/ecp.11.45

http://dx.doi.org/10.2217/pme.11.51


http://dx.doi.org/10.1038/scientificamerican0811-16

http://dx.doi.org/10.4161/mabs.3.4.16589


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1177/009286151104500403

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=730576

Kaitin KI. 21st Century innovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. *Pharmaceutical Technology*. 2011;35(6):32 [RS 3119]
http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id=724982&sk=&date=&&pageID=1

http://www.emaud.org/Doc/Market_Access_Newsletter_EMAUD_June%202011.pdf


Reichert JM. The amazing, multipurpose antibody. *mAbs*. 2011;3(3):221-222. [RS 3116b]
http://dx.doi.org/10.4161/mabs.3.3.15625

http://dx.doi.org/10.2217/pme.11.38

http://dx.doi.org/10.1177/009286151104500316

http://dx.doi.org/10.1177/009286151104500307


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kaitin KI, editor. New or modified indications for existing drugs have steadily increased in the U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Mar/Apr;13(2)** [RS 3111]

http://dx.doi.org/10.4161/mabs.3.2.14788

http://dx.doi.org/10.1177/009286151104500203

Getz KA. Low hanging fruit in the fight against inefficiency. *Applied Clinical Trials*. 2011;20(3):30-32 [RS 3109]
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Low-Hanging-Fruit-in-the-Fight-Against-Inefficiency/ArticleStandard/Article/detail/711311?contextCategoryId=37194

http://dx.doi.org/10.1038/clpt.2010.286


Getz KA. The ultimate act of appreciation of study volunteers. *Focus*. 2011;3:8-12 [RS 3106b]

http://dx.doi.org/10.4161/mabs.3.1.13895

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


[http://dx.doi.org/10.1038/nrd3296](http://dx.doi.org/10.1038/nrd3296)

[http://dx.doi.org/10.1177/009286151104500106](http://dx.doi.org/10.1177/009286151104500106)


Reichert JM. Metrics for antibody therapeutics development. *mAbs.* 2010;2(6):695-700 [RS 3029]
[http://dx.doi.org/10.4161/mabs.2.6.13603](http://dx.doi.org/10.4161/mabs.2.6.13603)

[http://dx.doi.org/10.1038/clpt.2010.167](http://dx.doi.org/10.1038/clpt.2010.167)

[http://dx.doi.org/10.1038/nbt1110-1160](http://dx.doi.org/10.1038/nbt1110-1160)

Getz KA. Hurry up and wait, pharma puts the brakes on strategic outsourcing partnering. *Inside Outsourcing.* 2010 Nov;10-16 [RS 3026b]
[http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12](http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=693552


Getz KA. Providing results to volunteers. Applied Clinical Trials. 2010;19(10):52-59 [RS 3023b]

Getz KA. Ominous clouds over outsourcing. Applied Clinical Trials. 2010;19(9):28-30 [RS 3023]
http://license.icopyright.net/rights/tag.act?tag=3.7442%3ficx_id=686210

http://dx.doi.org/10.1038/nrd3229

RS 3021 Vernon JA, Golec JH, DiMasi JA. Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Economics. 2010;19(8):1002-1005
http://dx.doi.org/10.1002/hec.1538


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=673673&sk=&date=&pageID=3

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 3016d Getz KA. Engaging pharmacists in research education. *Applied Clinical Trials.* 2010;19(7):30-32
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=678141

http://dx.doi.org/10.1038/clpt.2010.86

http://dx.doi.org/10.4161/mabs.12369

http://dx.doi.org/10.1093/jnci/djq246


http://dx.doi.org/10.1371/journal.pone.0010610


RS 3012 Getz K. FIPNet: Pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials.* 2009;Suppl:10-12,14,16

Author manuscript; available in PMC 2011 August 4. PMCID: PMC3150117

**This publication is for sale at our website  http://csdd.tufts.edu/reports
RS 3010b  Getz KA. Conversations with study volunteers. *Applied Clinical Trials*. 2010;19(5):32-34
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/Conversations-With-Study-Volunteers/ArticleStandard/Article/detail/668513


RS 3009  Getz KA. Sizing up the clinical research market. *Applied Clinical Trials*. 2010;19(3):32-34
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=660749

RS 3008  Getz KA. With clinical data, less is more. *Applied Clinical Trials*. 2010;19(1):28-30
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/With-Clinical-Data-Less-is-More/ArticleStandard/Article/detail/652123

http://dx.doi.org/10.1093/protein/gzq018

RS 3007b  Getz KA. Understanding clinical trials: Appreciating medical heroes. *Media Planet*. 2010 Apr


http://dx.doi.org/10.4161/mabs.2.2.11320

http://dx.doi.org/10.1097/MJT.0b013e3181ca7f10


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

RS 3004 Kaitin KI. Deconstructing the drug development process: The new face of innovation. *Clinical Pharmacology & Therapeutics.* 2010;87(3):356-61 http://dx.doi.org/10.1038/clpt.2009.293


RS 3002b Reichert JM. Antibodies to watch in 2010. *MAbs.* 2010;2(1):84-100; http://dx.doi.org/10.4161/mabs.2.1.10786


**This publication is for sale at our website http://csdd.tufts.edu/reports**

RS 2930 Getz KA. Assessing the downstream impact of protocol design complexity. Touch Briefings. 2009:93-5


http://dx.doi.org/10.1017/S0266462309090072


http://dx.doi.org/10.1126/scitranslmed.3000222

http://dx.doi.org/10.1007/BF03256155

RS 2924 Kaitin KI, editor. Drug approvals for neglected diseases increased along with more R&D funding. Tufts Center for the Study of Drug Development Impact Report. 2009 Nov/Dec;11(6)**

http://dx.doi.org/10.4161/mabs.1.6.10059


**This publication is for sale at our website  http://csdd.tufts.edu/reports

RS2921b  Getz KA.  Into the aftermath of M&A.  *Applied Clinical Trials*. 2009;18(9)  


http://dx.doi.org/10.4161/mabs.1.5.9675

RS 2920  Reichert JM.  Probabilities of success for antibody therapeutics.  *MAbs*.  
2009;1(4):387-9  
http://dx.doi.org/10.4161/mabs.1.4.9031


2009;43(4):493-500  
http://dx.doi.org/10.1177/009286150904300415


http://www.fdli.org/resources/resources-order-box-detail-view/off-label-use-reimbursement

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=609455


http://dx.doi.org/10.4161/mabs.1.4.9076


http://dx.doi.org/10.4161/mabs.1.1.7645


http://dx.doi.org/10.4161/mabs.1.3.8590


http://www.pharmexec.com/pharmexec/Sales+Articles/Make-a-Match/ArticleStandard/Article/detail/592061

http://dx.doi.org/10.1038/nbt0409-331

**This publication is for sale at our website http://csdd.tufts.edu/reports


RS 2905  Kaitin KI, editor. 75% of U.S. health plans reimburse off-label uses of prescription drugs. Tufts Center for the Study of Drug Development Impact Report. 2009 Mar/Apr;11(2)**


RS 2904c  Reichert JM. Letter from the editor. MAbs. 2009 Mar/Apr;1(2):91-92;  http://dx.doi.org/10.4161/mabs.1.2.7946


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.1097/MJT.0b013e31816b9027


http://www.washingtonpost.com/wp-dyn/content/article/2008/09/26/AR2008092603126_pf.html


RS 2825b  Getz KA. Getting to the heart of public distrust. *Applied Clinical Trials*. 2008;17(9):38-42


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/Is-Investigative-Site-Feasibility-Feasible/ArticleStandard/Article/detail/527735

http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing

http://www.manhattan-institute.org/html/mpr_06.htm


http://dx.doi.org/10.1002/9780471462422.eoct336


http://dx.doi.org/10.1215/03616878-2007-054

http://dx.doi.org/10.1215/03616878-2007-063


Getz KA. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update*. 2008;Apr;4:5-6

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1586/14737167.8.2.133


RS 2811 Getz KA. The heavy burden of protocol design. *Applied Clinical Trials.* 2008;17(5):38-40

RS 2810 Getz KA. Tackling racial disparities in research. *Applied Clinical Trials.* 2008;17(1):40-42

RS 2809 Getz KA. In search of efficiency between trial phases. *Applied Clinical Trials.* 2008;17(3):35-38
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Efficiency-Between-Trial-Phases/ArticleStandard/Article/detail/500433?contextCategoryId=37194

http://dx.doi.org/10.1097/MJT.0b013e31815fa75a


http://dx.doi.org/10.1177/009286150804200108

http://dx.doi.org/10.1016/j.drudis.2007.09.003

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1097/MJT.0b013e31815f9e52


RS 2802  Kaitin KI. Obstacles and opportunities in new drug development. *Clinical Pharmacology & Therapeutics.* 2008;83(2):210-2  
http://dx.doi.org/10.1038/sj.clpt.6100462


RS 2729  Getz KA. In search of informed consent improvement. *Applied Clinical Trials.* 2007;16(11):42-45  
http://www.actmagazine.com/appliedclinicaltrials/Clinical-Trial+Insights/In-Search-of-Informed-Consent-Improvement/ArticleStandard/Article/detail/468090

RS 2728  DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics.* 2007;82(5):488-90  
http://dx.doi.org/10.1038/sj.clpt.6100393

RS 2727  Cohen JP. CEA is not a price control (letter). *Health Affairs.* 2007;26(5):1505  
http://dx.doi.org/10.1377/hlthaff.26.5.1505

http://dx.doi.org/10.1108/17506120710818229

http://dx.doi.org/10.1007/s10198-006-0028-z

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Getz KA. CRO shifts in the outsourcing market. *Applied Clinical Trials.* 2007;16(5):35-38

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2707 Kaitin KI, editor. Pediatric study costs increased 8-fold since 2000 as complexity level grew. Tufts Center for the Study of Drug Development Impact Report. 2007 Mar/Apr;9(2)**


**This publication is for sale at our website http://csdd.tufts.edu/reports
http://dx.doi.org/10.2165/00063030-200721010-00001

http://dx.doi.org/10.1200/JCO.2006.09.0803


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454

http://www.the-scientist.com/?articles.view/articleNo/24559/title/Just-Another-Day-at-the-Office-/}

RS 2624b  Cohen J  Cairns C  Paquette C  Faden L.  Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy*. 2006;5(3):177-87  
http://dx.doi.org/10.2165/00148365-200605030-00004

http://dx.doi.org/10.2165/00148365-200605040-00009

http://dx.doi.org/10.1111/j.1365-2710.2006.00777.x

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Getz KA. Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence. *Applied Clinical Trials*. 2006;15(4):42-44
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473


http://dx.doi.org/10.1038/nrd1987

Kaitin KI, editor. CRO contribution to drug development is substantial and growing globally. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Jan/Feb;8(1)**

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=282477

**This publication is for sale at our website http://csdd.tufts.edu/reports**
RS 2601  Getz KA. The imperative to support site adoption of EDC. Applied Clinical Trials. 2006;15(1):38-40
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633

RS 2517  Getz KA. Have we pushed our PIs too far? Applied Clinical Trials. 2005;14(9):34-36
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&&pageID=1

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272

RS 2515  Milne C-P  Kaitin KI. Down the critical path: who should lead? Applied Clinical Trials. 2005;14(8):56
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279

http://dx.doi.org/10.2307/3564071

http://dx.doi.org/10.1056/NEJM200504283521723

RS 2512  DiMasi JA  Hansen RW  Grabowski HG. Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder. Journal of Health Economics. 2005 Sep;24(5):1049-53

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

Kaitin KI, editor. Longer clinical times are extending time to market for new drugs in U.S. *Tufts Center for the Study of Drug Development Impact Report.* 2005 Nov/Dec;7(6)**

Reichert JM Rosensweig CJ Faden LB Dewitz MC. Monoclonal antibody successes in the clinic. *Nature Biotechnology.* 2005;23(9):1073-8 http://dx.doi.org/10.1038/nbt0905-1073


http://dx.doi.org/10.1017/S0266462304001291

RS 2423  Milne C-P. Harbingers, or harvesters of change? *European Pharmaceutical Review Supplement (Outsourcing)*. 2004 Winter:12-17


http://dx.doi.org/10.1136/bmj.330.7481.39


http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12516


http://dx.doi.org/10.1038/nbt1204-1513

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

[http://dx.doi.org/10.1177/009286150403800301](http://dx.doi.org/10.1177/009286150403800301)


[http://dx.doi.org/10.1056/NEJM200405203502127](http://dx.doi.org/10.1056/NEJM200405203502127)

[http://dx.doi.org/10.1177/009286150303700401](http://dx.doi.org/10.1177/009286150303700401)


[http://dx.doi.org/10.1038/nrd1386](http://dx.doi.org/10.1038/nrd1386)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1177/009286150403800105


http://dx.doi.org/10.1016/S1359-6446(04)03025-9


http://dx.doi.org/10.1177/009286150303700403

http://dx.doi.org/10.1076/jmep.28.3.327.14586

http://dx.doi.org/10.1177/009286150303700310

http://dx.doi.org/10.1345/aph.1D110

http://dx.doi.org/10.1097/00045391-200309000-00010


**This publication is for sale at our website  http://csdd.tufts.edu/reports
RS 2312  Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report.* 2003 Sep/Oct;5(5)**


RS 2309  Reichert JM. Trends in development and approval times for new therapeutics in the United States. *Nature Reviews Drug Discovery.* 2003;2(9):695-703  http://dx.doi.org/10.1038/nrd1178


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
[http://dx.doi.org/10.1016/S0167-6296(02)00126-1](http://dx.doi.org/10.1016/S0167-6296(02)00126-1)

RS 2301 Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report.* 2003 Jan/Feb;5(1)**


[http://dx.doi.org/10.2165/00019053-200220003-00011](http://dx.doi.org/10.2165/00019053-200220003-00011)


RS 2218 Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. *Tufts Center for the Study of Drug Development Impact Report.* 2002 Nov/Dec;4(6)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

[http://dx.doi.org/10.1038/nbt0802-780](http://dx.doi.org/10.1038/nbt0802-780)


[http://dx.doi.org/10.1038/nbt0702-659](http://dx.doi.org/10.1038/nbt0702-659)

RS 2211  Cohen J  Chee J. Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. *Disease Management & Health Outcomes.* 2002;10(4):221-7  
[http://dx.doi.org/10.1177/009286150103500228](http://dx.doi.org/10.1177/009286150103500228)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2204  Kaitin KI. From the Editor-in-Chief: regulatory reform at the crossroads. *Drug Information Journal. 2002;36(2):245-6*

RS 2203  Reichert JM  Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics. 2002;4(2):110-8*


RS 2123  Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) *La Vanguardia* (Barcelona). 2001 18 Mar*


http://dx.doi.org/10.1038/nbt0901-819

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.2165/00019053-200119070-00004


http://dx.doi.org/10.1177/009286150103500228


http://dx.doi.org/10.1177/009286150103500203


http://dx.doi.org/10.1067/mcp.2001.115446

http://dx.doi.org/10.1067/mcp.2001.115132


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Kaitin KI, editor. FDA’s fast track program results in 62% approval rate after first 3 years. *Tufts Center for the Study of Drug Development Impact Report*. 2001 Jan/Feb;3(1)**


Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Dec;2(9)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.2165/00019053-200018001-00001

http://dx.doi.org/10.1017/S0963180100903116

http://dx.doi.org/10.1097/01.COT.0000293239.37468.b0


http://dx.doi.org/10.1016/S0167-7799(00)01473-6


http://dx.doi.org/10.1177/009286150003400303

http://www.acnp.org/g4/GN401000182/Default.htm

http://dx.doi.org/10.1177/009286150003400304


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Drug firms embrace pediatric study program during first 2 years of FDAMA. *Tufts Center for the Study of Drug Development Impact Report.* 2000 Apr;2(3)

http://dx.doi.org/10.1001/jama.283.15.2013


http://dx.doi.org/10.1177/009286150003400129


http://dx.doi.org/10.1177/009286150003400101


http://dx.doi.org/10.1177/009286159903300401


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 9912 | Planning, independence, feedback keep global R&D projects on track. *Tufts Center for the Study of Drug Development Impact Report*. 1999 Sep;1(3) |

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
http://dx.doi.org/10.1177/00928615980320S103


RS 9810  Lasagna L.  Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine. *Journal of Clinical Pharmacology.* 1998;38:570-1, 575-6  
http://dx.doi.org/10.1002/j.1552-4604.1998.tb04460.x


http://dx.doi.org/10.1056/NEJM199804233381722


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.3109/J058v12n02_01


http://www.jstor.org/stable/20644671

http://dx.doi.org/10.1016/S0009-9236(97)90026-6


http://dx.doi.org/10.2165/00019053-199712030-00004

http://dx.doi.org/10.1177/009286159703100319


**This publication is for sale at our website** http://csdd.tufts.edu/reports


RS 9714 Lasagna L DiMasi JA. Let’s speed up the approval of new indications for old drugs. Medical Marketing & Media 1996;31(12):88-9

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1016/S0009-2366(96)90209-X

http://dx.doi.org/10.1177/009286159603000416

RS 9625 DiMasi JA. *Written testimony.* House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996


RS 9623 Kaitin KI. *Statement.* Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform, February 27, 1996. 104th Congress 2d Session:81-7, 100-1


http://archive.wilsonquarterly.com/essays/research-dilemma


RS 9618 Welling PG  Lasagna L  Banakar UV, editors. *The drug development process.* New York; Marcel Dekker:1996*

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1177/009286159603000103


http://dx.doi.org/10.1097/00045391-199609000-00008


http://dx.doi.org/10.1177/009286159603000201


**This publication is for sale at our website**  
http://csdd.tufts.edu/reports
http://dx.doi.org/10.2165/00019053-199609020-00004

http://dx.doi.org/10.1097/00004714-199512000-00001

http://dx.doi.org/10.1097/00045391-199509000-00023

http://dx.doi.org/10.1016/0009-9236(95)90240-6

http://dx.doi.org/10.1177/009286159502900227

RS 9506  Shulman SR  Seibring M  Manocchia M. *Letter to Hon. Judd Gregg, U.S. Senate.* Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8


http://dx.doi.org/10.1097/00004714-199504000-00002


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9594  Bloom BR. The United States needs a national vaccine authority. *Science.* 1994 Sep 2;265(5177):1378-80. [http://dx.doi.org/10.1126/science.8073275]


**This publication is for sale at our website** [http://csdd.tufts.edu/reports]
http://www.fdli.org/mobile/resources-detail-view/?friendlyname=the-drug-export-amendments-act-of-1986-is-it-all-it-was-intended-to-be

http://dx.doi.org/10.1215/03616878-19-4-922


http://dx.doi.org/10.1002/j.1552-4604.1994.tb02044.x

RS 9496  Lasagna L.  *Statement of Louis Lasagna, M.D., Dean, Tufts Sackler School of Graduate Biomedical Sciences at the National Institutes of Health CRADA forum, July 21, 1994.*  Washington DC: New England Biomedical Research Coalition, 1994


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News.* 1993 Nov;(8)


Shulman SR Raiford DS. Promotional elements in educational programs: FDA attempts to wipe the slate clean. P&T. 1992;17:661-73*


**This publication is for sale at our website [http://csdd.tufts.edu/reports]**
http://dx.doi.org/10.1177/009286159202600305

http://dx.doi.org/10.1177/009286159202600105

http://dx.doi.org/10.1038/clpt.1991.97

http://dx.doi.org/10.1038/nbt0592-521


Scoville B. Shifting the burden: restructuring the drug review process. *Journal of Clinical Pharmacology and Therapeutics.* 1991;49(3):229-33
http://dx.doi.org/10.1038/clpt.1991.21


http://dx.doi.org/10.1038/clpt.1991.172

http://dx.doi.org/10.1056/NEJM199108013250513

**This publication is for sale at our website**  http://csdd.tufts.edu/reports


Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News.* 1991 Aug;(7)


**This publication is for sale at our website [http://csdd.tufts.edu/reports]**


RS 9054  Shulman SR. La legislazione sulla responsabilità di produzione. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:27-8

RS 9053  Lasagna L. Le attività del Centro per lo Studio dello Sviluppo dei Farmaci. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26

RS 9052  Inman WHW. Drug Safety Research Unit, University of Southampton, *PEM News*. 1988 Sep(5)


[http://dx.doi.org/10.1177/009286159002400135](http://dx.doi.org/10.1177/009286159002400135)

[http://dx.doi.org/10.1177/009286159002400132](http://dx.doi.org/10.1177/009286159002400132)

RS 9048  Shulman SR  Raiford DS. FDA regulations provide broader access to unapproved drugs. *Journal of Clinical Pharmacology*. 1990;30(2):585-7  


[http://dx.doi.org/10.1177/009286158902300406](http://dx.doi.org/10.1177/009286158902300406)


http://dx.doi.org/10.2105/AJPH.79.11.1565

http://dx.doi.org/10.1177/009286158802200104

http://dx.doi.org/10.1002/j.1552-4604.1989.tb03249.x

Kaitin KI. Reply to “understanding comparisons of drug introductions between the United States and the United Kingdom”. *Clinical Pharmacology & Therapeutics.* 1989 Aug;46(2):146-8
http://dx.doi.org/10.1038/clpt.1989.118


http://dx.doi.org/10.1002/j.1552-4604.1989.tb03402.x


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/clpt.1989.116


RS 8934  Grabowski HG.  Medicaid patients' access to new drugs.  *Health Affairs* 1989;7:102-14  
http://dx.doi.org/10.1377/hlthaff.7.5.102

http://dx.doi.org/10.1001/jama.1988.03410150098038

http://dx.doi.org/10.1016/0273-2300(88)90007-4

http://dx.doi.org/10.1016/0273-2300(88)90013-X

RS 8930  Inman WHW.  Drug Safety Research Unit, University of Southampton.  *PEM News.* 1988 Sep;(5)


RS 8830  Shulman SR.  Drug refusal policy must include legal definition of competence.  *Hospital Formulary.* 1988 Jan;23:79

RS 8829  DiMasi JA.  The notion of "acceptable risk": comment.  *Journal of Clinical Epidemiology.* 1988;41(9):939-41  
http://dx.doi.org/10.1016/0895-4356(88)90111-4

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1002/j.1552-4604.1988.tb05747.x

Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? *Cancer Treatment Reports.* 1987;71(9):795-806


http://dx.doi.org/10.1038/clpt.1988.35

http://dx.doi.org/10.1287/mnsc.33.3.381

http://dx.doi.org/10.1002/mde.4090070404


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1002/j.1552-4604.1987.tb03064.x


http://dx.doi.org/10.3109/10601338709032965


http://dx.doi.org/10.2131/jts.12.439


http://dx.doi.org/10.1038/clpt.1987.42

http://dx.doi.org/10.7326/0003-4819-106-6-886


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Inman WHW. Drug Safety Research Unit, University of Southampton, *PEM News.* 1987 Mar;(4)

http://dx.doi.org/10.1177/009286158501900327

http://dx.doi.org/10.1038/clpt.1986.192


http://dx.doi.org/10.1002/j.1552-4604.1986.tb02950.x

Kaitin KI. Impact of generic drugs on the pharmaceutical marketplace. *Private Practice.* 1986 Sep;18:18-20 (Originally appeared as "Generic firms shun research, share rewards.")

http://dx.doi.org/10.1016/0273-2300(86)90006-1


http://dx.doi.org/10.1111/j.1365-2125.1987.tb03099.x

http://dx.doi.org/10.1001/jama.1986.03380180128035

**This publication is for sale at our website** http://csdd.tufts.edu/reports


[http://dx.doi.org/10.1017/S0266462300003445](http://dx.doi.org/10.1017/S0266462300003445)


[http://dx.doi.org/10.1080/00031305.1985.10479435](http://dx.doi.org/10.1080/00031305.1985.10479435)


RS 8600  Berry CL.  Unprovable verities.  *Human Toxicology.* 1985;5(3):159-60

RS 8699  Weintraub M  Northington F.  Drugs that wouldn't die.  *Journal of the American Medical Association.*  1986 May 2;255(17):2327-8  
[http://dx.doi.org/10.1001/jama.1986.03370170091042](http://dx.doi.org/10.1001/jama.1986.03370170091042)

[http://dx.doi.org/10.1177/009286158602000105](http://dx.doi.org/10.1177/009286158602000105)


RS 8696  Inman WHW.  Drug Surveillance Research Unit, University of Southampton.  *PEM News.* 1985 Dec;(3)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kitch E. Vaccines and product liability: a case of contagious litigation. Regulation. 1985 May/Jun


Walker SR Schultz E Schuppan D Gelzer J. A comparative retrospective analysis of data for short- and long-term animal toxicity studies on 40 pharmaceutical compounds. Archives of Toxicology. 1984; Suppl 7:485-7 http://dx.doi.org/10.1007/978-3-642-69132-4_102


Mattison N. Sources of change affecting the U.S. pharmaceutical industry in the 1980s. Pharmaceutical Medicine. 1985;1:89-96*


**This publication is for sale at our website http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1002/j.1552-4604.1985.tb02819.x

http://dx.doi.org/10.1038/clpt.1985.54

http://dx.doi.org/10.1002/ddr.430040402


http://dx.doi.org/10.1038/clpt.1984.224


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
Inman WHW. Drug Surveillance Research Unit, University of Southampton, *PEM News*. 1984 Aug;(2)


Hutt PB. The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. *Health Affairs*. 1982;1(2):5-24 [http://dx.doi.org/10.1377/hlthaff.1.2.6](http://dx.doi.org/10.1377/hlthaff.1.2.6)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1001/jama.1983.03330400070028


RS 8367  Superior Court of New Jersey, Appellate Division. Carol Ann Feldman, an infant, by her parent and guardian *ad litem* Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

RS 8366  Inman WHW.  Drug Surveillance Research Unit, University of Southampton. *PEM News.* 1983 Aug;(1)

RS 8365  Covington TR.  Toward a rational approach to the issue of prescribing authority for pharmacists. *Drug Intelligence and Clinical Pharmacy.* 1983;17(9):660-6

http://dx.doi.org/10.1038/clpt.1983.95

http://www.jstor.org/stable/41110241


**This publication is for sale at our website**  http://csdd.tufts.edu/reports
http://dx.doi.org/10.1038/clpt.1983.73

http://dx.doi.org/10.1038/clpt.1982.181

http://dx.doi.org/10.1136/bmj.283.6289.477

http://dx.doi.org/10.1111/j.1365-2125.1981.tb01251.x


http://dx.doi.org/10.1007/BF00396431

http://dx.doi.org/10.1007/BF00332351

http://dx.doi.org/10.1016/S0272-0590(82)80089-4

RS 8357b  Mahler H.  Essential drugs for all.  *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982*;64-70

RS 8357  Lall S.  The pharmaceutical industry in India: the economic costs of regulation.  *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982*;51-7


RS 8262  Wardell WM. Is pharmaceutical innovation declining? *Pharmaceutical Technology.* 1982 Sep


RS 8260  Wardell WM Mattison N. The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis. In: *WMA Follow-up Committee on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association;1982;84-98*


http://dx.doi.org/10.1002/j.1552-4604.1982.tb02664.x


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8253b  Schweiker RS. Remarks by the Honorable Richard S. Schweiker to the National Pharmaceutical Council Symposium. June 23, 1982


http://dx.doi.org/10.1038/clpt.1982.34

RS 8250  Wardell WM. A statement on pharmaceutical patent life and innovation. Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982


http://dx.doi.org/10.1001/jama.1981.03310450044021


RS 8153  Wardell WM Velo GP, editors. Drug development, regulatory assessment, and postmarketing surveillance. NATO Advanced Institutes Series, 39 (Series A: Life Sciences) New York: Plenum; 1981*
http://dx.doi.org/10.1007/978-1-4684-4055-3


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.1016/0010-7824(81)90025-1


http://dx.doi.org/10.1056/NEJM197912273012602


**This publication is for sale at our website**  http://csdd.tufts.edu/reports
Bonchek LI. Are randomized trials appropriate for evaluating new operations? 
*New England Journal of Medicine.* 1979 Jul 5;301(21):44-5 
http://dx.doi.org/10.1056/NEJM197907053010110


Hansen RW. Effects of incremental costs on pharmaceutical innovation. (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

Hansen RW. The cost of regulation in the pharmaceutical industry: economic implications of three recent studies. (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association, 1980:139-50*

Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). *Private Practice.* 1980 Oct:24-31*


http://dx.doi.org/10.1002/j.1552-4604.1980.tb01660.x

Lasagna L. Pharmacology’s labs have moved faster than the regulators. *Medical Tribune.* 1980 May 7;21:17

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)

http://dx.doi.org/10.7326/0003-4819-92-3-419


Hansen RW. *Pharmaceutical development costs by therapeutic categories.* (Working Paper Series No. GPB-80-6) Rochester, NY: Graduate School of Management, University of Rochester; Mar 1980*


http://dx.doi.org/10.1007/BF01968667

**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)

http://dx.doi.org/10.1038/clpt.1980.160


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 7939  Lasagna L. Toxicological barriers to providing better drugs. *Archives of Toxicology.* 1979;43(1):27-33

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 7927  Wardell WM. Rx: more regulation or better therapies. Regulation. 1979 Sep/Oct;3(5):25-33

RS 7926b Lasagna L. The diseases and drug needs of the Third World. Journal of Chronic Diseases. 1979;32(6):413-4
http://dx.doi.org/10.1016/0021-9681(79)90101-2


http://dx.doi.org/10.1001/jama.1978.03280450060031

http://dx.doi.org/10.1126/science.644328


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1007/BF01968666


RS 7823  Wardell WM. A close inspection of the 'calm look': rhetorical amblyopia and selective amnesia at the FDA. *Journal of the American Medical Association.* 1978;239(19):2004-11
http://dx.doi.org/10.1001/jama.1978.03280460072023


PS 7816  Landau RL. *What you should know about estrogens, or the perils of Pauline.* Rochester, NY: Center for the Study of Drug Development; Jun 1978


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1046/j.1537-2995.1977.174772168


**This publication is for sale at our website http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1007/BF03284217

http://dx.doi.org/10.1056/NEJM197702032960505


http://dx.doi.org/10.1097/00012995-197608000-00001


**This publication is for sale at our website  http://csdd.tufts.edu/reports


